Acute and delayed nausea and emesis control in pediatric oncology patients

Cancer

Volumn 106, Issue 4, 2006, Pages 931-940

  Holdsworth, Mark T ^a   Raisch, Dennis W ^b   Frost, Jami ^c  

^a UNIVERSITY OF NEW MEXICO   (United States)

^b University of New Mexico   (United States)

^c UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

Author keywords

Chemotherapy; Children; Control; Emesis; Nausea; Pediatrics

Indexed keywords

ANTINEOPLASTIC AGENT; ASPARAGINASE; BLEOMYCIN; CARBOPLATIN; CISPLATIN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYTARABINE; DACTINOMYCIN; DAUNORUBICIN; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; HYDROCORTISONE; IFOSFAMIDE; MERCAPTOPURINE; METHOTREXATE; ONDANSETRON; TOPOTECAN; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; CANCER PATIENT; CHEMOTHERAPY INDUCED EMESIS; CHILD; CHILDHOOD CANCER; CLINICAL PRACTICE; DISEASE SEVERITY; EWING SARCOMA; FEMALE; GENDER; GROUPS BY AGE; HODGKIN DISEASE; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; NEUROBLASTOMA; NEWBORN; PRIORITY JOURNAL; REVIEW; RHABDOMYOSARCOMA;

ACUTE DISEASE; ADOLESCENT; ADULT; AGE FACTORS; ANTIEMETICS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CHILD, PRESCHOOL; FEMALE; HEALTH SURVEYS; HUMANS; INFANT; INFANT, NEWBORN; MALE; NAUSEA; NEOPLASMS; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME; VOMITING;

EID: 32544433481     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.21631     Document Type: Review

References (21)

1. de Boer-Dennert M, de Wit R, Schmitz PIM, et al. Patient perceptions of the side-effects of chemotherapy: the influence of 5HT3 antagonists. Br J Cancer. 1997;76:1055-1061.
2. Small BE, Holdsworth MT, Raisch DW, Winter SS. Survey ranking of emetogenic control in children receiving chemotherapy. J Pediatr Hematol Oncol. 2000;22:125-132.
3. Holdsworth MT, Adams VR, Raisch DW, Wood JG, Winter SS. Computerized system for outcomes-based antiemetic therapy in children. Ann Pharmacother. 2000;34:1101-1108.
4. Italian Group for Antiemetic Research. Cisplatin-induced delayed emesis: pattern and prognostic factors during three subsequent cycles. Ann Oncol. 1994;5:585-589.
5. Kris MG, Pisters KMW, Hinkley L. Delayed emesis following anticancer chemotherapy. Support Care Cancer. 1994;2:297-300.
6. 3 receptor antagonists in the control of cisplatin-induced delayed emesis. Oncology. 1996;53(Suppl 1):78-85.
7. Latreille J, Pater J, Johnston D, et al. Use of dexamethasone and granisetron in the control of delayed emesis for patients who receive highly emetogenic chemotherapy. J Clin Oncol. 1998;16:1174-1178.
8. Italian Group for Antiemetic Research. Prevention of cisplatin-induced delayed emesis: still unsatisfactory. Support Care Cancer. 1999;8:229-232.
9. Roila F, Donati D, Tamberi S, Margutti G. Delayed emesis: incidence, pattern, prognostic factors and optimal treatment. Support Care Cancer. 2002;10:88-95.
10. Dupuis LL, Lau R, Greenberg ML. Delayed nausea and vomiting in children receiving antineoplastics. Med Pediatr Oncol 2001;37:115-121.
11. Holdsworth MT, Raisch DW, Duncan MH, Chavez CM, Leasure MM. Assessment of chemotherapy-induced emesis and evaluation of a reduced-dose intravenous ondansetron regimen in pediatric outpatients with leukemia. Ann Pharmacother. 1995;29:16-21.
12. ASHP Commission on Therapeutics. ASHP therapeutic guidelines on the pharmacologic management of nausea and vomiting in adult and pediatric patients receiving chemotherapy or radiation therapy or undergoing surgery. Am J Health Syst Pharm. 1999;56:729-764.
13. Gralla RI, Osoba D, Kris MG, et al. Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. J Clin Oncol. 1999;17:2971-2994.
14. Multinational Association for Supportive Care in Cancer. Antiemetic guidelines. March, 2004. Available at URL: http://www.mascc.org [accessed May 15, 2005].
15. Linet MS, Ries LAG, Smith MA, Tarone RE, Devesa SS. Cancer surveillance series: recent trends in childhood cancer incidence and mortality in the United States. J Natl Cancer Inst. 1999;91:1051-1058.
16. Hickok JT, Roscoe JA, Morrow GR, King DK, Atkins JN, Fitch TR. Nausea and emesis remain significant problems of chemotherapy despite prophylaxis with 5-hydroxytryptamine-3 antiemetics. Cancer. 2003;97:2880-6.
17. Grunberg SM, Deuson RR, Mavros P, et al. Incidence of chemotherapy-induced nausea and emesis after modern antiemetics. Perception versus reality. Cancer. 2004;100:2261-2268.
18. Watamura SE, Donzella B, Kertes DA, Gunnar MR. Developmental changes in baseline cortisol activity in early childhood: relations with napping and effortful control. Dev Psychobiol. 2004;45:125-133.
19. Fredrikson M, Hursti T, Furst CJ, et al. Nausea in cancer chemotherapy is inversely related to urinary cortisol excretion. Br J Cancer. 1992;65:779-780.
20. Zeltzer LK, LeBaron S, Zeltzer PM. A prospective assessment of chemotherapy-related nausea and vomiting in children with cancer. Am J Pediatr Hematol Oncol. 1984;6:5-16.
21. Zeltzer L, LeBaron S, Zeltzer PM. Paradoxical effects of prophylactic phenothiazine anti-emetics in children receiving chemotherapy. J Clin Oncol. 1984;2:930-936.